Page last updated: 2024-08-26

lopinavir and Diseases, Metabolic

lopinavir has been researched along with Diseases, Metabolic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arroyo, JA; Baldovi, F; de Lazzari, E; Domingo, P; Galindo, MJ; Gatell, JM; Larrousse, M; León, A; Martínez, E; Milinkovic, A	1
Carosi, G; De Luca, A; Di Giambenedetto, S; Lo Caputo, S; Micheli, V; Patroni, A; Quiros-Roldan, E; Regazzi-Bonora, M; Torti, C; Villani, P	1

Trials

1 trial(s) available for lopinavir and Diseases, Metabolic

Article	Year
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. Journal of acquired immune deficiency syndromes (1999), 2004, Mar-01, Volume: 35, Issue:3 Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Lipids; Lopinavir; Male; Metabolic Diseases; Pyrimidinones; Reproducibility of Results	2004

Other Studies

1 other study(ies) available for lopinavir and Diseases, Metabolic

Article	Year
Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-01, Volume: 38, Issue:7 Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Cholesterol, HDL; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Diseases; Pyrimidinones; Risk Factors; Ritonavir; Triglycerides	2004

Article

Year

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-01, Volume: 38, Issue:7

Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Cholesterol, HDL; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Diseases; Pyrimidinones; Risk Factors; Ritonavir; Triglycerides

2004